Skip to main content
. 2022 Oct 28;6(1):33–36. doi: 10.1002/iju5.12542

Fig. 2.

Fig. 2

Pathological manifestation of mUC in Lynch syndrome. The pathological features of bone metastatic lesion (a: hematoxylin and eosin, ×400, b: anti‐uroplakin‐2 immunostaining, ×400) and immune‐histochemical presentation of the primary renal pelvic tumor (c: anti‐MSH2 immunostaining, ×400, d: anti‐MSH6 immunostaining, ×400).